Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021

Business Wire May 19, 2021

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire May 14, 2021

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire May 6, 2021

Gilead Sciences Announces Second Quarter 2021 Dividend

Business Wire April 29, 2021

Gilead Sciences Announces First Quarter 2021 Financial Results

Business Wire April 29, 2021

Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India

Business Wire April 26, 2021

Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021

Business Wire April 15, 2021

U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer

Business Wire April 13, 2021

FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Business Wire April 7, 2021

NeuroRx Announces Zyesami(TM) (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

PR Newswire April 6, 2021

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Business Wire April 1, 2021

Gilead Sciences Comments on the Passing of John C. Martin, PhD

Business Wire March 31, 2021

Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research

Business Wire March 26, 2021

European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer

Business Wire March 25, 2021

Gilead and Novo Nordisk Expand NASH Clinical Collaboration

Business Wire March 18, 2021

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Business Wire March 15, 2021

Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

Business Wire March 9, 2021

Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI

Business Wire March 6, 2021

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

Business Wire March 5, 2021

Gilead Sciences Completes Acquisition of MYR GmbH

Business Wire March 4, 2021